EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Assessment of polymeric mucin–drug interactions

Hisanao Kishimoto iD, Caroline Ridley, Katsuhisa Inoue, David J Thornton iD

PLOS ONE · 27.06.2024 · 19 (6) · e0306058

DOI: 10.1371/journal.pone.0306058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 27.06.2024. Verfasst von Hisanao Kishimoto und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, Japan. Hauptthemen laut MEDLINE: Paclitaxel, Mucin 5AC. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Mochida Memorial Foundation for Medical and Pharmaceutical Research, JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mucosal-delivered drugs have to pass through the mucus layer before absorption through the epithelial cell membrane. Although there has been increasing interest in polymeric mucins, a major structural component of mucus, potentially acting as important physiological regulators of mucosal drug absorption, there are no reports that have systematically evaluated the interaction between mucins and drugs. In this study, we assessed the potential interaction between human polymeric mucins (MUC2, MUC5B, and MUC5AC) and various drugs with different chemical profiles by simple centrifugal method and fluorescence analysis. We found that paclitaxel, rifampicin, and theophylline likely induce the aggregation of MUC5B and/or MUC2. In addition, we showed that the binding affinity of drugs for polymeric mucins varied, not only between individual drugs but also among mucin subtypes. Furthermore, we demonstrated that deletion of MUC5AC and MUC5B in A549 cells increased the cytotoxic effects of cyclosporin A and paclitaxel, likely due to loss of mucin-drug interaction. In conclusion, our results indicate the necessity to determine the binding of drugs to mucins and their potential impact on the mucin network property.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelMucin 5ACHumansA549 CellsDrug InteractionsMucin-5BMucinsMucin-2RifampinCyclosporineProtein Binding

Substanzen

PaclitaxelMucin 5ACMucin-5BMUC5AC protein, humanMucinsMucin-2RifampinCyclosporineMUC5B protein, humanMUC2 protein, human

Autor:innen und Institutionen

  • Department of Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, Japan.
  • Wellcome Centre for Cell-Matrix Research, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom.

ORCID-Profile: Hisanao Kishimoto, David J Thornton

Förderung

  • Wellcome Trust
  • Mochida Memorial Foundation for Medical and Pharmaceutical Research
  • JSPS KAKENHI
  • The Helen Muir Fund
  • The Wellcome Centre for Cell-Matrix Research is supported by core funding from Wellcome

Zitieren

APA

Kishimoto, H., Ridley, C., Inoue, K., & Thornton, D. J. (2024). Assessment of polymeric mucin–drug interactions. PLOS ONE, 19(6), e0306058. https://doi.org/10.1371/journal.pone.0306058

Vancouver

Kishimoto H, Ridley C, Inoue K, Thornton DJ. Assessment of polymeric mucin–drug interactions. PLOS ONE. 2024;19(6):e0306058. doi:10.1371/journal.pone.0306058

BibTeX
@article{Kishimoto2024,
  author = {Kishimoto, Hisanao and Ridley, Caroline and Inoue, Katsuhisa and Thornton, David J},
  title = {Assessment of polymeric mucin–drug interactions},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {6},
  pages = {e0306058},
  doi = {10.1371/journal.pone.0306058}
}
Kostenlos starten →